ASCO 2024 | Phase III TROPICS-04 trial: sacituzumab govitecan vs treatment of choice in advanced mUC
Arlene Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the recent press release of the Phase III TROPiCS-04 (NCT04527991) trial, a global, multicenter, open-label, randomized, controlled trial of sacituzumab govitecan versus treatment of physician’s choice in patients with locally advanced unresectable or metastatic urothelial carcinoma (mUC) who progressed after prior platinum-based and checkpoint inhibitor therapies. The trial did not meet the standard to improve survival, raising concerns about the toxicity of sacituzumab govitecan. She highlights her curiosity about the trial’s detailed results and suggests that the toxicity of sacituzumab govitecan, particularly neutropenia and neutropenic fevers, might be a contributing factor. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
